Dr Paolo Gallipoli
Clinical Senior Lecturer
Haematology
Queen Mary University of London
Queen Mary University of London
Research
Acute myeloid leukaemia, Biology, Metabolism, Therapy
Interests
We use in vitro models to study the biology and therapy of acute myeloid leukaemia. We always strive to make our models more relevant. For example we have now developed coculture systems to grow leukaemia cells with several different stromal cells and are able to show differences in the leukaemia cell behaviour which are likely more reflective of what happens in vivoPublications
Publications of specific relevance to Predictive in vitro Models
2024
Othman J, Tiong IS, O'Nions J, Dennis M, Mokretar K, Ivey A, Austin M, Latif A-L, Amer M, Chan WY, Crawley C, Crolla F, Cross J, Dang R, Elliot J, Fong CY, Galli S, Gallipoli P, Hogan F, Kalkur P, Khan A, Krishnamurthy P, Laurie J, Loo S, Marshall S, Mehta P, Murthy V, Nagumantry S, Pillai S and Potter N (2024). Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy. American Society of Hematology Blood vol. 143, (4) 336-341. 10.1182/blood.2023021579
Dembitz V, Durko J, Campos J, James SC, Lawson H, Kranc KR and Gallipoli P (2024). Immunodeficient NBSGW mouse strain allows chemotherapy modeling in AML patient‐derived xenografts. Wiley Hemasphere vol. 8, (1) 10.1002/hem3.28
2023
Milojkovic D, Blijlevens N, Kwong Y-L, Zaidi U, Castagnetti F, Gallipoli P, Miggiano MC, Westerweel PE, Chen M, Hernandez MCG, Kell WJ, Vachhani P, Agarwal N, Colasante A, Meka S, Smyth A, Ferreira G and Janssen JJWM (2023). Real-World Effectiveness of Asciminib in Patients with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: A Global Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP). American Society of Hematology Blood vol. 142, (Supplement 1) 10.1182/blood-2023-181937
Dokal A, Borek WE, Nobre L, Pedicona SF, Wrench B, Gallipoli P, Arruda A, Campbell AE, Nawaz N, Ferguson HR, Perkins DN, Moreno-Cardoso P, Thompson A, Williamson AJK, Minden MD, Gribben JG, Britton DJ and Cutillas PR (2023). S124: PHOSPHOPROTEOMICS ACCURATELY PREDICTS RESPONSES TO MIDOSTAURIN PLUS CHEMOTHERAPY IN TWO INDEPENDENT COHORTS OF FLT3 MUTANT-POSITIVE ACUTE MYELOID LEUKAEMIA. Wiley Hemasphere vol. 7, (S3) 10.1097/01.hs9.0000967408.39207.65
Philippe C, Mian S, Maniati E, Protopapa P, Bergot T, Piganeau M, Nemkov T, Di Bella D, Morales V, Finch A, D’Alessandro A, Bianchi K, Wang J, Gallipoli P, Kordasti S, Kubasch AS, Cross M, Platzbecker U, Wiseman D, Bonnet D, Bernard D, Gribben J and Rouault-Pierre K (2023). O20 TARGETING THE DEFECTIVE COA PATHWAY TO IMPROVE ERYTHROPOIESIS IN SF3B1-MUTANT MDS-RS PATIENTS. Elsevier Leukemia Research vol. 128, 10.1016/j.leukres.2023.107133
Woodley K, Dillingh LS, Giotopoulos G, Madrigal P, Rattigan KM, Philippe C, Dembitz V, Magee AMS, Asby R, van de Lagemaat LN, Mapperley C, James SC, Prehn JHM, Tzelepis K, Rouault-Pierre K, Vassiliou GS, Kranc KR, Helgason GV, Huntly BJP and Gallipoli P (2023). Mannose metabolism inhibition sensitizes acute myeloid leukaemia cells to therapy by driving ferroptotic cell death. Springer Nature Nature Communications vol. 14, (1) 10.1038/s41467-023-37652-0
Fernando F, Innes AJ, Claudiani S, Pryce A, Hayden C, Byrne J, Gallipoli P, Copland M, Apperley JF and Milojkovic D (2023). The outcome of post-transplant asciminib in patients with chronic myeloid leukaemia. Springer Nature Bone Marrow Transplantation vol. 58, (7) 826-828. 10.1038/s41409-023-01975-9
Sabatier M, Birsen R, Lauture L, Mouche S, Angelino P, Dehairs J, Goupille L, Boussaid I, Heiblig M, Boet E, Sahal A, Saland E, Santos JC, Armengol M, Fernández-Serrano M, Farge T, Cognet G, Simonetta F, Pignon C, Graffeuil A, Mazzotti C, Avet-Loiseau H, Delos O, Bertrand-Michel J, Chedru A, Dembitz V, Gallipoli P, Anstee NS, Loo S and Wei AH (2023). C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress-Induced Ferroptosis in FLT3-Mutant Leukemia. American Association For Cancer Research (Aacr) Cancer Discovery vol. 13, (7) 1720-1747. 10.1158/2159-8290.cd-22-0411
Mian SA, Philippe C, Maniati E, Protopapa P, Bergot T, Piganeau M, Nemkov T, Di Bella D, Morales V, Finch AJ, D’Alessandro A, Bianchi K, Wang J, Gallipoli P, Kordasti S, Kubasch AS, Cross M, Platzbecker U, Wiseman DH, Bonnet D, Bernard DG, Gribben JG and Rouault-Pierre K (2023). Vitamin B5 and succinyl-CoA improve ineffective erythropoiesis in SF3B1-mutated myelodysplasia. American Association For The Advancement of Science (Aaas) Science Translational Medicine vol. 15, (685) eabn5135-eabn5135. 10.1126/scitranslmed.abn5135
2022
Dembitz V, Lawson H, Philippe C, Burt RJ, James S, Magee ASM, Woodley K, Durko J, Campos J, Austin MJ, Rio-Machin A, Izquierdo PC, Bewicke-Copley F, Blanco GR, Patel B, Hazlehurst L, Peck B, Finch A, Cutillas P, Fitzgibbon J, Yuneva M, Rouault-Pierre K, Copland J, Kranc K and Gallipoli P (2022). Inhibition of Stearoyl-CoA Desaturase Has Anti-Leukemic Properties in Acute Myeloid Leukemia. American Society of Hematology Blood vol. 140, (Supplement 1) 3058-3060. 10.1182/blood-2022-166811
Lawson H, Holt-Martyn J, Dembitz V, Durko J, Kabayama Y, Wang L, Van De Lagemaat L, Dubusse L, Alunno L, Guitart A, Schwaller J, Gallipoli P, O'Carroll D, Schofield C and Kranc K (2022). Targeting HIF-Hydroxylases Compromises Disease Initiation and Propagation, and Synergises with Current Therapies to Eliminate Cancer Stem Cells in AML. American Society of Hematology Blood vol. 140, (Supplement 1) 8731-8732. 10.1182/blood-2022-165192
Innes AJ, Hayden C, Orovboni V, Rees D, Claudiani S, Fernando F, Khan A, Byrne J, Gallipoli P, Francis S, Copland M, Horne G, Raghavan M, Arnold C, Collins A, Cranfield T, Cunningham N, Danga A, Forsyth P, Frewin R, Garland P, Hannah G, Hassan S, Huntly BJP, Husain J, Makkuni S, Rothwell K, Foroni L, Apperley JF and Milojkovic D (2022). Real-World Experience of Asciminib: Factors Associated with Response. American Society of Hematology Blood vol. 140, (Supplement 1) 6796-6797. 10.1182/blood-2022-165501
Othman J, Tiong IS, Mokretar K, Ivey A, Austin MJ, Latif A-L, Crawley C, Amer M, Crolla F, Cross JW, Dang R, Fong CY, Galli S, Gallipoli P, Hogan FL, Kalkur P, Khan A, Krishnamurthy P, Laurie J, Marshall SR, Murthy V, Nagumantry SK, Pillai S, Potter N, Taylor T, Zhao R, Wei AH and Dillon R (2022). Molecular MRD Assessment Is Strongly Prognostic in Patients with NPM1 Mutated AML Receiving Venetoclax Based Non-Intensive Therapy. American Society of Hematology Blood vol. 140, (Supplement 1) 2033-2035. 10.1182/blood-2022-159467
Gallipoli P (2022). AML gets upSET when its dietary needs are unMet. American Society of Hematology Blood vol. 140, (19) 2003-2004. 10.1182/blood.2022018008
Dawson MA, Borthakur G, Huntly B, Karadimitris A, Alegre A, Chaidos A, Vogl DT, Pollyea DA, Davies FE, Morgan GJ, Glass J, Kamdar M, Manteca M-VM, Tovar N, Yeh P, Delgado RG, Basheer F, Marando L, Gallipoli P, Wyce A, Krishnatry AS, Barbash O, Bakirtzi E, Ferron-Brady G, Karpinich NO, McCabe MT, Foley SW, Horner T, Dhar A and Kremer BE (2022). A phase I/II open-label study of molibresib for the treatment of relapsed/refractory hematologic malignancies. American Association For Cancer Research (Aacr) Clinical Cancer Research vol. 29, (4) 711-722. 10.1158/1078-0432.ccr-22-1284
Innes A, Orovboni V, Claudiani S, Fernando F, Khan A, Byrne J, Gallipoli P, Copland M, Horne G, Arnold C, Collins A, Cunningham N, Danga A, Frewin R, Garland P, Hannah G, Hassan S, Makkuni S, Rothwell K, Foroni L, Hayden C, Apperley J and Milojkovic D (2022). P706: ASCIMINIB USE IN CML: THE UK EXPERIENCE. Wiley Hemasphere vol. 6, 601-602. 10.1097/01.hs9.0000845708.96602.91
Gallipoli P, Clark RE, Byrne J, Apperley JF, Milojkovic D, Foroni L, Goldman JM and O’Brien S (2022). The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia. Wiley British Journal of Haematology vol. 196, (6) e55-e57. 10.1111/bjh.17961
2021
Mian S, Philippe C, Maniati E, Bergot T, Piganeau M, Di Bella D, Morales V, Finch A, Bianchi K, Wang J, Gallipoli P, Platzbecker U, Wiseman DH, Bonnet D, Bernard D, Gribben J and Rouault-Pierre K (2021). Vitamin B5 and Succinyl-CoA Improve Ineffective Erythropoiesis in SF3B1 Mutated Myelodysplasia. American Society of Hematology Blood vol. 138, (Supplement 1) 10.1182/blood-2021-147726
Woodley K, Dillingh LS, Giotopoulos G, Madrigal P, Tzelepis K, Philippe C, Rattigan K, Asby R, Dembitz V, Magee ASM, Helgason G, Rouault-Pierre K, Vassiliou GS, Huntly BJP and Gallipoli P (2021). Mannose Metabolism Is a Metabolic Vulnerability Unveiled By Standard and Novel Therapies in Acute Myeloid Leukemia. American Society of Hematology Blood vol. 138, (Supplement 1) 10.1182/blood-2021-148489
Othman J, Afzal U, Amofa R, Austin MJ, Bashford A, Belsham E, Byrne J, Coats T, Dang R, Dennis M, Dhawan S, Elliot J, Francis S, Gallipoli P, Hodgson K, Kallmeyer C, Jain M, Katsomitrou V, Khan A, Khwaja A, Kolade S, Krishnamurthy P, Latif A, Laurie J, Lim M, Loke CT, Manson C, Marshall SR, Mobashwera B and Munisamy S (2021). Gilteritinib for Relapsed Acute Myeloid Leukaemia with FLT3 Mutation during the COVID-19 Pandemic: Real World Experience from the UK National Health Service. American Society of Hematology Blood vol. 138, (Supplement 1) 10.1182/blood-2021-150169
Othman J, Amer M, Amofa R, Anderson L, Austin MJ, Bashford A, Belsham E, Boot J, Campbell VL, Coats T, Collins A, Crawley C, Crolla F, Cross JW, Dalley C, Dang R, Dennis M, Dhawan S, Elliott J, Galli S, Gallipoli P, Hodgson K, Jain M, Kalkur P, Katsomitrou V, Khan A, Khwaja A, Krishnamurthy P, Latif A and Laurie J (2021). Venetoclax with Azacitidine or Low Dose Cytarabine As an Alternative to Intensive Chemotherapy in Fit Adults during the COVID19 Pandemic: Real World Data from the UK National Health Service. American Society of Hematology Blood vol. 138, (Supplement 1) 10.1182/blood-2021-149685
Yun H, Narayan N, Vohra S, Giotopoulos G, Mupo A, Madrigal P, Sasca D, Lara-Astiaso D, Horton SJ, Agrawal-Singh S, Meduri E, Basheer F, Marando L, Gozdecka M, Dovey OM, Castillo-Venzor A, Wang X, Gallipoli P, Müller-Tidow C, Osborne CS, Vassiliou GS and Huntly BJP (2021). Mutational synergy during leukemia induction remodels chromatin accessibility, histone modifications and three-dimensional DNA topology to alter gene expression. Springer Nature Nature Genetics vol. 53, (10) 1443-1455. 10.1038/s41588-021-00925-9
Dembitz V and Gallipoli P (2021). The Role of Metabolism in the Development of Personalized Therapies in Acute Myeloid Leukemia. Frontiers Frontiers in Oncology vol. 11, 10.3389/fonc.2021.665291
Hughes CFM, Gallipoli P and Agarwal R (2021). Design, implementation and clinical utility of next generation sequencing in myeloid malignancies: acute myeloid leukaemia and myelodysplastic syndrome. Elsevier Pathology 10.1016/j.pathol.2021.01.005
2020
Forte D, García-Fernández M, Sánchez-Aguilera A, Stavropoulou V, Fielding C, Martín-Pérez D, López JA, Costa ASH, Tronci L, Nikitopoulou E, Barber M, Gallipoli P, Marando L, de Castillejo CLF, Tzankov A, Dietmann S, Cavo M, Catani L, Curti A, Vázquez J, Frezza C, Huntly BJ, Schwaller J and Méndez-Ferrer S (2020). Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy. Elsevier Cell Metabolism vol. 32, (5) 829-843.e9. 10.1016/j.cmet.2020.09.001
Castelli R, Bergamaschini L, Teatini T, Cilumbriello L, Schiavon R, Gallipoli P and Deliliers GL (2020). Does Outcome/Survival of Patients With Myelodysplastic Syndromes Should Be Predicted by Reduced Levels of ADAMTS-13? Results From a Pilot Study. Elsevier Clinical Lymphoma Myeloma & Leukemia vol. 20, (8) e461-e467. 10.1016/j.clml.2019.12.016
Horne GA, Stobo J, Kelly C, Mukhopadhyay A, Latif AL, Dixon-Hughes J, McMahon L, Cony-Makhoul P, Byrne J, Smith G, Koschmieder S, BrÜmmendorf TH, Schafhausen P, Gallipoli P, Thomson F, Cong W, Clark RE, Milojkovic D, Helgason GV, Foroni L, Nicolini FE, Holyoake TL and Copland M (2020). A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. Springer Nature Leukemia vol. 34, (7) 1775-1786. 10.1038/s41375-019-0700-9
2019
Sasca D, Yun H, Giotopoulos G, Szybinski J, Evan T, Wilson NK, Gerstung M, Gallipoli P, Green AR, Hills R, Russell N, Osborne CS, Papaemmanuil E, Göttgens B, Campbell P and Huntly BJP (2019). Cohesin-dependent regulation of gene expression during differentiation is lost in cohesin-mutated myeloid malignancies. American Society of Hematology Blood vol. 134, (24) 2195-2208. 10.1182/blood.2019001553
Claudiani S, Metelli S, Kamvar R, Szydlo R, Khan A, Byrne J, Gallipoli P, Bulley SJ, Horne GA, Rothwell K, Copland M, Clark RE, Khorashad JS, Foroni L, Milojkovic D and Apperley JF (2019). Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML). American Society of Hematology Blood vol. 134, (Supplement_1) 10.1182/blood-2019-131500
Basheer F, Giotopoulos G, Meduri E, Yun H, Mazan M, Sasca D, Gallipoli P, Marando L, Gozdecka M, Asby R, Sheppard O, Dudek M, Bullinger L, Döhner H, Dillon R, Freeman S, Ottmann O, Burnett A, Russell N, Papaemmanuil E, Hills R, Campbell P, Vassiliou GS and Huntly BJP (2019). Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML. Rockefeller University Press Journal of Experimental Medicine vol. 216, (4) 966-981. 10.1084/jem.20181276
Gallipoli P and Huntly BJP (2019). Histone modifiers are oxygen sensors. American Association For The Advancement of Science (Aaas) Science vol. 363, (6432) 1148-1149. 10.1126/science.aaw8373
Gallipoli P and Huntly BJP (2019). Prognostic Models Turn the Heat(IT)up on FLT3ITD-Mutated AML. American Association For Cancer Research (Aacr) Clinical Cancer Research vol. 25, (2) 460-462. 10.1158/1078-0432.ccr-18-3146
2018
Tzelepis K, De Braekeleer E, Aspris D, Barbieri I, Vijayabaskar MS, Liu W-H, Gozdecka M, Metzakopian E, Toop HD, Dudek M, Robson SC, Hermida-Prado F, Yang YH, Babaei-Jadidi R, Garyfallos DA, Ponstingl H, Dias JML, Gallipoli P, Seiler M, Buonamici S, Vick B, Bannister AJ, Rad R, Prinjha RK, Marioni JC, Huntly B, Batson J, Morris JC, Pina C and Bradley A (2018). SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4. Springer Nature Nature Communications vol. 9, (1) 10.1038/s41467-018-07620-0
Castelli R, Gallipoli P, Schiavon R, Teatini T, Deliliers GL and Bergamaschini L (2018). Increased risk of heparin induced thrombocytopenia and thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. Springer Nature Journal of Thrombosis and Thrombolysis vol. 47, (1) 155-156. 10.1007/s11239-018-1773-4
Gallipoli P (2018). JAK of all trades: Ruxolitinib as a new therapeutic option for CML patients. Elsevier Leukemia Research vol. 75, 71-72. 10.1016/j.leukres.2018.10.010
Gallipoli P, Giotopoulos G, Tzelepis K, Costa ASH, Vohra S, Medina-Perez P, Basheer F, Marando L, Di Lisio L, Dias JML, Yun H, Sasca D, Horton SJ, Vassiliou G, Frezza C and Huntly BJP (2018). Glutaminolysis is a metabolic dependency in FLT3ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition. American Society of Hematology Blood vol. 131, (15) 1639-1653. 10.1182/blood-2017-12-820035
2017
Castelli R, Gallipoli P, Schiavon R, Teatini T, Deliliers GL and Bergamaschini L (2017). High prevalence of heparin induced thrombocytopenia with thrombosis among patients with essential thrombocytemia carrying V617F mutation. Springer Nature Journal of Thrombosis and Thrombolysis vol. 45, (1) 106-113. 10.1007/s11239-017-1566-1
Gallipoli P and Huntly BJP (2017). Novel epigenetic therapies in hematological malignancies: Current status and beyond. Elsevier Seminars in Cancer Biology vol. 51, 198-210. 10.1016/j.semcancer.2017.07.005
2016
Tarafdar A, Hopcroft LE, Gallipoli P, Pellicano F, Cassels J, Hair A, Korfi K, Jørgensen HG, Vetrie D, Holyoake TL and Michie AM (2016). CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression. Blood 10.1182/blood-2016-09-742049
Tzelepis K, Koike-Yusa H, De Braekeleer E, Li Y, Metzakopian E, Dovey OM, Mupo A, Grinkevich V, Li M, Mazan M, Gozdecka M, Ohnishi S, Cooper J, Patel M, McKerrell T, Chen B, Domingues AF, Gallipoli P, Teichmann S, Ponstingl H, McDermott U, Saez-Rodriguez J, Huntly BJP, Iorio F, Pina C, Vassiliou GS and Yusa K (2016). A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia. Elsevier Cell Reports vol. 17, (4) 1193-1205. 10.1016/j.celrep.2016.09.079
Scott MT, Korfi K, Saffrey P, Hopcroft LE, Kinstrie R, Pellicano F, Guenther C, Gallipoli P, Cruz M, Dunn K, Jorgensen HG, Cassels JE, Hamilton A, Crossan A, Sinclair A, Holyoake TL and Vetrie D (2016). Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition. American Association For Cancer Research Cancer Discovery vol. 6, (11) 1248-1257. 10.1158/2159-8290.CD-16-0263
Gidaro A, Deliliers GL, Gallipoli P, Arquati M, Wu MA and Castelli R (2016). Laboratory and clinical risk assessment to treat myelodysplatic syndromes. De Gruyter Clinical Chemistry and Laboratory Medicine vol. 54, (9) 1411-1426. 10.1515/cclm-2015-0789
2015
Castelli R, Pantaleo G, Gallipoli P, Gidaro A, Arquati M, Wu MA and Deliliers GL (2015). Salvage therapy with bortezomib and dexamethasone in elderly patients with relapsed/refractory multiple myeloma. Wolters Kluwer Anti-Cancer Drugs vol. 26, (10) 1078-1082. 10.1097/cad.0000000000000285
Giotopoulos G, van der Weyden L, Osaki H, Rust AG, Gallipoli P, Meduri E, Horton SJ, Chan W-I, Foster D, Prinjha RK, Pimanda JE, Tenen DG, Vassiliou GS, Koschmieder S, Adams DJ and Huntly BJP (2015). A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression. Rockefeller University Press Journal of Experimental Medicine vol. 212, (10) 1551-1569. 10.1084/jem.20141661
Hopcroft LEM, Calderhead B, Gallipoli P, Holyoake TL and Girolami MA (2015). Bayesian inference for model selection: an application to aberrant signalling pathways in chronic myeloid leukaemia. Systems Genetics Cambridge University Press (Cup) 10.1017/cbo9781139012751.009
Gallipoli P, Giotopoulos G and Huntly BJP (2015). Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia. Sage Publications Therapeutic Advances in Hematology vol. 6, (3) 103-119. 10.1177/2040620715577614
Giotopoulos G, Chan W-I, Horton SJ, Ruau D, Gallipoli P, Fowler A, Crawley C, Papaemmanuil E, Campbell PJ, Göttgens B, Van Deursen JM, Cole PA and Huntly BJP (2015). The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia. Springer Nature Oncogene vol. 35, (3) 279-289. 10.1038/onc.2015.92
2014
Gallipoli P, Cook A, Rhodes S, Hopcroft L, Wheadon H, Whetton AD, Jørgensen HG, Bhatia R and Holyoake TL (2014). JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo. American Society of Hematology Blood vol. 124, (9) 1492-1501. 10.1182/blood-2013-12-545640
Colombo R, Gallipoli P and Castelli R (2014). Thrombosis and Hemostatic Abnormalities in Hematological Malignancies. Elsevier Clinical Lymphoma Myeloma & Leukemia vol. 14, (6) 441-450. 10.1016/j.clml.2014.05.003
Castelli R, Deliliers GL, Colombo R, Moreo G, Gallipoli P and Pantaleo G (2014). Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function. Springer Nature Annals of Hematology vol. 93, (9) 1523-1529. 10.1007/s00277-014-2070-8
2013
Giotopoulos G, Chan W-I, Ruau D, Gallipoli P, Fowler A, Göttgens B, Van Deursen J, Cole P and Huntly B (2013). The Epigenetic Regulators CBP and p300 Facilitate Leukemogenesis and Represent Therapeutic Targets In Acute Myeloid Leukemia (AML). American Society of Hematology Blood vol. 122, (21) 10.1182/blood.v122.21.3732.3732
Gallipoli P, Pellicano F, Morrison H, Laidlaw K, Allan EK, Bhatia R, Copland M, Jørgensen HG and Holyoake TL (2013). Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation. American Society of Hematology Blood vol. 122, (19) 3335-3339. 10.1182/blood-2013-02-485607
Gallipoli P, Stobo J, Heaney N, Nicolini FE, Clark R, Wilson G, Tighe J, McLintock L, Hughes T, Michor F, Paul J, Drummond M and Holyoake TL (2013). Safety and efficacy of pulsed imatinib with or without G‐CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow‐up. Wiley British Journal of Haematology vol. 163, (5) 674-676. 10.1111/bjh.12532
Chen M, Gallipoli P, DeGeer D, Sloma I, Forrest DL, Chan M, Lai D, Jorgensen H, Ringrose A, Wang HM, Lambie K, Nakamoto H, Saw KM, Turhan A, Arlinghaus R, Paul J, Stobo J, Barnett MJ, Eaves A, Eaves CJ, Holyoake TL and Jiang X (2013). Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1–BCR-ABL–JAK2 Complex. Oxford University Press (Oup) Journal of The National Cancer Institute vol. 105, (6) 405-423. 10.1093/jnci/djt006
McIlwaine L, Parker A, Sandilands G, Gallipoli P and Leach M (2013). Neutrophil‐specific granule deficiency. Wiley British Journal of Haematology vol. 160, (6) 735-735. 10.1111/bjh.12207
2012
Shah M, Gallipoli P, Lyons J, Holyoake T and Jørgensen H (2012). Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro. Elsevier Blood Cells Molecules and Diseases vol. 48, (3) 199-201. 10.1016/j.bcmd.2012.01.005
2011
Gallipoli P, Abraham SA and Holyoake TL (2011). Hurdles Toward a Cure for CML: The CML Stem Cell. Elsevier Hematology/Oncology Clinics of North America vol. 25, (5) 951-966. 10.1016/j.hoc.2011.09.001
Gallipoli P, Shepherd P, Irvine D, Drummond M and Holyoake T (2011). Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study. Wiley British Journal of Haematology vol. 155, (1) 128-130. 10.1111/j.1365-2141.2011.08653.x
2010
DeGeer D, Gallipoli P, Chen M, Sloma I, Jorgensen H, Forrest D, Lambie K, Nakamoto H, Saw KM, Chan M, Newmarch K, Zhou L, Turhan AG, Arlinghaus RB, Eaves AC, Eaves CJ, Holyoake TL and Jiang X (2010). Combined Targeting of BCR-ABL and JAK2 with ABL and JAK2 Inhibitors Is Effective Against CML Patients' Leukemic Stem/Progenitor Cells. American Society of Hematology Blood vol. 116, (21) 10.1182/blood.v116.21.3404.3404
2009
Hamilton A, Gallipoli P, Nicholson E and Holyoake TL (2009). Targeted therapy in haematological malignancies. Wiley The Journal of Pathology vol. 220, (4) 404-418. 10.1002/path.2669
Gallipoli P, Clark A and Leach M (2009). The evolving management of a rare lymphoproliferative disorder–T‐cell prolymphocytic leukemia. Wiley American Journal of Hematology vol. 84, (11) 750-753. 10.1002/ajh.21498
Fyfe AJ and Gallipoli P (2009). Multiple splenic calcifications. Wiley British Journal of Haematology vol. 144, (6) 808-808. 10.1111/j.1365-2141.2008.07420.x
Gallipoli P, Drummond M and Leach M (2009). Hemophagocytosis and relapsed peripheral T‐cell lymphoma. Wiley European Journal of Haematology vol. 82, (3) 246-246. 10.1111/j.1600-0609.2008.01167.x
Gallipoli P and Drummond M (2009). Pseudotumour cerebri as a manageable side effect of prolonged all‐trans retinoic acid therapy in an adult patient with acute promyelocytic leukaemia. Wiley European Journal of Haematology vol. 82, (3) 242-243. 10.1111/j.1600-0609.2008.01185.x
2008
Gallipoli P, Tang A and Leach M (2008). Cortical blindness due to sagittal sinus thrombosis in acute lymphoblastic leukaemia. Wiley British Journal of Haematology vol. 145, (3) 270-270. 10.1111/j.1365-2141.2008.07462.x
2007
Gallipoli P and Leach M (2007). Gingival infiltration in acute monoblastic leukaemia. Springer Nature British Dental Journal vol. 203, (9) 507-509. 10.1038/bdj.2007.994
2005
Finelli C, Gallipoli P, Celentano E, Cacace G, Saldalamacchia G, De Caprio C, Contaldo F and Pasanisi F (2005). Assessment of physical activity in an outpatient obesity clinic in southern Italy: Results from a standardized questionnaire. Elsevier Nutrition Metabolism and Cardiovascular Diseases vol. 16, (3) 168-173. 10.1016/j.numecd.2005.05.002
2002
Gallipoli P (2002). Medical education: Britain versus Italy. Bmj The Bmj vol. 324, (Suppl S2) 10.1136/sbmj.020232
Gallipoli P (2002). Glasgow: a very interesting place. Bmj The Bmj vol. 324, (Suppl S2) 10.1136/sbmj.020231
1992
Clark JA, Deutch AY, Gallipoli PZ and Amara SG (1992). Functional expression and CNS distribution of a β-alanine-sensitive neuronal GABA transporter. Elsevier Neuron vol. 9, (2) 337-348. 10.1016/0896-6273(92)90172-a
Grants
Grants of specific relevance to Predictive in vitro Models
DISSECTING THE ROLE OF MANNOSE METABOLISM IN LEUKEMIA AND NORMAL STEM CELL FUNCTION
Gallipoli P
£320,237 Barts Charity (01-03-2023 - 01-03-2026)
Gallipoli P
£320,237 Barts Charity (01-03-2023 - 01-03-2026)
IDENTIFICATION AND CHARACTERISATION OF METABOLIC PATHWAYS AS DETERMINANTS OF DRUG RESISTANCE IN ACUTE MYELOID LEUKAEMIA
Woodley K, Gallipoli P and Dembitz V
£1,427,000 Cancer Research UK (01-10-2019 - 30-09-2024)
Woodley K, Gallipoli P and Dembitz V
£1,427,000 Cancer Research UK (01-10-2019 - 30-09-2024)
THE ROLE OF ABERRANT METABOLISM IN THE PATHOGENESIS AND THERAPY OF ACUTE MYELOID LEUKAEMIA (AML).
Gallipoli P
£393,467 Wellcome Trust (01-04-2016 - 01-10-2019)
Gallipoli P
£393,467 Wellcome Trust (01-04-2016 - 01-10-2019)
The relevance of autocrine growth factor activation to the survival and proliferation of primitive CML cells
Gallipoli P
£203,583 Medical Research Council (30-09-2010 - 28-02-2013)
Gallipoli P
£203,583 Medical Research Council (30-09-2010 - 28-02-2013)